Skip to Content

Artificial Intelligence May Discover the Next Blockbuster Drug

Ken Mulvaney, CEO of Benevolent AI, discusses the opportunities and challenges that come with applying machine learning to drug development.
June 12, 2017

AI is revolutionizing countless industries, but its biggest impact may be felt in medicine. Machine learning has proved capable of identifying signs of disease in medical images and records, and it may become invaluable for analyzing vast genomic data sets for clues as to the origins of different disorders. Benevolent AI, headquartered in London, is working to apply the latest AI techniques to the identification and development of novel drug compounds. The company’s CEO, Ken Mulvaney, met with MIT Technology Review’s senior editor for AI, Will Knight, to discuss AI’s relevance to drug discovery and medicine, and to talk about his company’s ambitious plans.

Keep Reading

Most Popular

A Roomba recorded a woman on the toilet. How did screenshots end up on Facebook?

Robot vacuum companies say your images are safe, but a sprawling global supply chain for data from our devices creates risk.

A startup says it’s begun releasing particles into the atmosphere, in an effort to tweak the climate

Make Sunsets is already attempting to earn revenue for geoengineering, a move likely to provoke widespread criticism.

10 Breakthrough Technologies 2023

Every year, we pick the 10 technologies that matter the most right now. We look for advances that will have a big impact on our lives and break down why they matter.

These exclusive satellite images show that Saudi Arabia’s sci-fi megacity is well underway

Weirdly, any recent work on The Line doesn’t show up on Google Maps. But we got the images anyway.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.